259 related articles for article (PubMed ID: 37035180)
1. Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT.
Chen Z; Zhen S; Zhang T; Shen Y; Pang A; Yang D; Zhang R; Ma Q; He Y; Wei J; Zhai W; Chen X; Jiang E; Han M; Feng S
Front Oncol; 2023; 13():1137175. PubMed ID: 37035180
[TBL] [Abstract][Full Text] [Related]
2. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
[TBL] [Abstract][Full Text] [Related]
3. Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients.
Yang TT; Song XL; Zhao YM; Ye BD; Luo Y; Xiao HW; Chen Y; Fu HR; Yu J; Liu LZ; Lai XY; Ye YS; Lan JP; Huang H; Shi JM
Ann Hematol; 2022 Dec; 101(12):2731-2741. PubMed ID: 36318288
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
Daver NG; Iqbal S; Renard C; Chan RJ; Hasegawa K; Hu H; Tse P; Yan J; Zoratti MJ; Xie F; Ramsingh G
J Hematol Oncol; 2023 Mar; 16(1):19. PubMed ID: 36879351
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
Maiti A; Qiao W; Sasaki K; Ravandi F; Kadia TM; Jabbour EJ; Daver NG; Borthakur G; Garcia-Manero G; Pierce SA; Montalbano KS; Pemmaraju N; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Takahashi K; Yilmaz M; Jain N; Kornblau SM; Andreeff M; Bose P; Ferrajoli A; Issa GC; Masarova L; Thompson PA; Rausch CR; Ning J; Kantarjian HM; DiNardo CD; Konopleva MY
Am J Hematol; 2021 Mar; 96(3):282-291. PubMed ID: 33264443
[TBL] [Abstract][Full Text] [Related]
6. Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial.
Liu Y; Li Y; Zhang R; Yu Z; Jing Y
Front Immunol; 2023; 14():1269163. PubMed ID: 38054008
[TBL] [Abstract][Full Text] [Related]
7. Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis.
Sutter T; Schittenhelm M; Volken T; Lehmann T
Hematology; 2023 Dec; 28(1):2206694. PubMed ID: 38078486
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.
Lachowiez CA; Loghavi S; Kadia TM; Daver N; Borthakur G; Pemmaraju N; Naqvi K; Alvarado Y; Yilmaz M; Short N; Ohanian M; Pierce SR; Patel KP; Qiao W; Ning J; Sasaki K; Takahashi K; Jabbour E; Andreeff M; Ravandi F; Kantarjian HM; Konopleva M; DiNardo CD
Blood Adv; 2020 Apr; 4(7):1311-1320. PubMed ID: 32251497
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of Venetoclax in the treatment of 25 patients with recurrent hematologic malignancies after an allogeneic hematopoietic stem cell transplantation].
Chen X; Liu ZY; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; He Y; Wei JL; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2022 Jul; 43(7):542-549. PubMed ID: 36709130
[No Abstract] [Full Text] [Related]
10. Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia.
Xu X; Liu R; He A; Wang F
Hematology; 2023 Dec; 28(1):2265206. PubMed ID: 37796109
[TBL] [Abstract][Full Text] [Related]
11. A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia.
Bang SY; Park S; Kwag D; Lee JH; Min GJ; Park SS; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Lee JW; Kim HJ
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980551
[TBL] [Abstract][Full Text] [Related]
12. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.
Short NJ; Venugopal S; Qiao W; Kadia TM; Ravandi F; Macaron W; Dinardo CD; Daver N; Konopleva M; Borthakur G; Shpall EJ; Popat U; Champlin RE; Mehta R; Al-Atrash G; Oran B; Jabbour E; Garcia-Manero G; Issa GC; Montalban-Bravo G; Yilmaz M; Maiti A; Kantarjian H
J Hematol Oncol; 2022 Jan; 15(1):12. PubMed ID: 35093134
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of Therapeutic Efficacy between Hypomenthylating Agents Combined with Venetoclax and Half Dose Priming Regimen in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia].
Xu MZ; Qiao M; Sun AN; Wu DP; Xue SL; Zhou HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1631-1636. PubMed ID: 36476881
[TBL] [Abstract][Full Text] [Related]
14. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
[No Abstract] [Full Text] [Related]
15. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
[TBL] [Abstract][Full Text] [Related]
16. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia.
Rausch CR; DiNardo CD; Maiti A; Jammal NJ; Kadia TM; Marx KR; Borthakur G; Savoy JM; Pemmaraju N; DiPippo AJ; Daver NG; Chew SM; Sasaki K; Issa GC; Short NJ; Takahashi K; Ohanian MN; Ning J; Xiao L; Alvarado Y; Kontoyiannis DP; Ravandi F; Kantarjian HM; Konopleva MY
Cancer; 2021 Jul; 127(14):2489-2499. PubMed ID: 33793970
[TBL] [Abstract][Full Text] [Related]
17. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
Maiti A; DiNardo CD; Qiao W; Kadia TM; Jabbour EJ; Rausch CR; Daver NG; Short NJ; Borthakur G; Pemmaraju N; Yilmaz M; Alvarado Y; Montalbano KS; Wade A; Maduike RE; Guerrero JA; Vaughan K; Bivins CA; Pierce S; Ning J; Ravandi F; Kantarjian HM; Konopleva MY
Cancer; 2021 Nov; 127(22):4213-4220. PubMed ID: 34343352
[TBL] [Abstract][Full Text] [Related]
18. A retrospective comparison of salvage intensive chemotherapy
Park S; Kwag D; Kim TY; Lee JH; Lee JY; Min GJ; Park SS; Yahng SA; Jeon YW; Shin SH; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Lee JW; Kim HJ
Ther Adv Hematol; 2022; 13():20406207221081637. PubMed ID: 35340720
[TBL] [Abstract][Full Text] [Related]
19. The approach of HMA plus VEN with or without BMT for all patients with AML.
Male HJ; Lin TL
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):186-191. PubMed ID: 38066860
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
Zhao P; Ni M; Ma D; Fang Q; Zhang Y; Li Y; Huang Y; Chen Y; Chai X; Zhan Y; Li Y; Kang Q; Zhao M; Liu M; Zhang F; Huang S; Wen S; Deng B; Wang J
Ann Hematol; 2022 Jan; 101(1):119-130. PubMed ID: 34568973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
